Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome
- 15 June 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 162 (1) , 123-128
Abstract
Background CD158k/KIR3DL2 is a specific marker for Sézary cells which can be used to diagnose Sézary syndrome (SS) in erythrodermic patients with abnormal circulating T cells. Objectives To evaluate the suitability of CD158k/KIR3DL2 for detecting and evaluating blood tumour load during the follow up of patients with SS. Methods The absolute CD3+ CD158k+ lymphocyte count was compared with the absolute count of cytomorphological Sézary cells and was correlated with clinical flares in a cohort of patients with SS. Twenty‐five patients were included in the study and 48 blood samples were analysed. Results The absolute count of CD3+ CD158k+ cells strongly correlated with the absolute count of atypical circulating cells (r = 0·97, P < 10−15). The CD3+ CD158k+ lymphocyte cell count was in eight cases more sensitive than cytomorphology for detecting atypical circulating cells especially for small‐sized tumour cells. The tumour burden evaluated by CD3+ CD158k+ immunostaining was significantly associated with clinical flare (P < 10−4). Conclusions CD3+ CD158k+ phenotyping is a reliable and objective test to monitor the blood tumour burden in patients with SS under systemic therapy.Keywords
This publication has 19 references indexed in Scilit:
- The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markersBritish Journal of Dermatology, 2008
- The Usefulness of CD26 in Flow Cytometric Analysis of Peripheral Blood in Sézary SyndromeAmerican Journal of Clinical Pathology, 2008
- CD158k/KIR3DL2 is a useful marker for identifying neoplastic T‐cells in Sézary syndrome by flow cytometryCytometry Part B: Clinical Cytometry, 2007
- A Comparison of Morphologic Features, Flow Cytometry, TCR-VβAnalysis, and TCR-PCR in Qualitative and Quantitative Assessment of Peripheral Blood Involvement by Sézary SyndromeAmerican Journal of Clinical Pathology, 2006
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- CD158k/KIR3DL2 Is a New Phenotypic Marker of Sezary Cells: Relevance for the Diagnosis and Follow-Up of Sezary SyndromeJournal of Investigative Dermatology, 2004
- Variable CD7 Expression on T Cells in the Leukemic Phase of Cutaneous T Cell Lymphoma (Sézary Syndrome)Journal of Investigative Dermatology, 2001
- Absence of CD26 Expression Is a Useful Marker for Diagnosis of T-Cell Lymphoma in Peripheral BloodAmerican Journal of Clinical Pathology, 2001
- Circulating Sezary cells in hospitalized dermatology patientsBritish Journal of Dermatology, 1978
- Cytogenetic, Cytophotometric, and Ultrastructural Study of Large Cerebriform Cells of the Sézary Syndrome and Description of a Small-Cell Variant23JNCI: Journal of the National Cancer Institute, 1973